Publicaciones en colaboración con investigadores/as de Clínica Universitaria de Navarra (15)

2024

  1. Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer

    Clinical Cancer Research, Vol. 30, Núm. 14, pp. 2945-2953

2023

  1. The Regulators of Peroxisomal Acyl-Carnitine Shuttle CROT and CRAT Promote Metastasis in Melanoma

    Journal of Investigative Dermatology, Vol. 143, Núm. 2, pp. 305-316.e5

2022

  1. Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor

    European Journal of Cancer, Vol. 174, pp. S116

  2. Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer

    Cancer Discovery, Vol. 12, Núm. 5, pp. 1356-1377

2019

  1. Use of machine-learning algorithms in intensified preoperative therapy of pancreatic cancer to predict individual risk of relapse

    Cancers, Vol. 11, Núm. 5

2018

  1. Revisiting interleukin-12 as a cancer immunotherapy agent

    Clinical Cancer Research, Vol. 24, Núm. 12, pp. 2716-2718

2017

  1. Brachytherapy attains abscopal effects when combined with immunostimulatory monoclonal antibodies

    Brachytherapy, Vol. 16, Núm. 6, pp. 1246-1251

  2. Interleukin-8 in cancer pathogenesis, treatment and follow-up

    Cancer Treatment Reviews, Vol. 60, pp. 24-31

2011

  1. Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy

    European Journal of Cancer, Vol. 47, Núm. 6, pp. 839-847

2010

  1. Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients

    British Journal of Cancer, Vol. 103, Núm. 10, pp. 1529-1535

  2. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): A dose-finding study and pharmacogenomic analysis

    British Journal of Cancer, Vol. 102, Núm. 6, pp. 987-994

2008

  1. Preliminary results of the combination of bevacizumab and weekly paclitaxel in advanced melanoma

    Oncology, Vol. 74, Núm. 1-2, pp. 12-16

2007

  1. Acquired nasopharyngeal stenosis: Surgical treatment for this unusual complication after chemoradiation for nasopharyngeal carcinoma

    Otolaryngology- Head and Neck Surgery, Vol. 137, Núm. 6, pp. 959-961

  2. Is there any reason to delay introduction of tumor necrosis factor in the management of in-transit metastasis of unresectable melanoma? [13]

    Journal of Clinical Oncology

  3. Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumab

    Clinical and Translational Oncology, Vol. 9, Núm. 2, pp. 119-120